Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with a placebo, according to the results of a new study led in part by co-author Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research and director of the Comprehensive Weight Control Center, part of the Division of Endocrinology, Diabetes, and Metabolism in the Weill Department...
Jane J. Seley, DNP, MPH, MSN, Clinical Assistant Professor of Medicine in the Division of Endocrinology, Diabetes and Metabolism, recently received the Allene Von Son Distinguished Service Award during the Association of Diabetes Care & Education Specialists (ADCES) annual meeting in New Orleans on Aug. 9, 2024. A Diabetes Nurse Practitioner and Certified Diabetes Care and Education Specialist, Dr. Seley co-presented in multiple presentations including F22 - Make Our Dreams Come True for...
In the latest episode of Weill Cornell Medicine's Back to Health podcast, Dr. Anyanate Gwendolyne Jack and Rachel Stahl Salzman, M.S. discuss what patients should know about recent advancements in obesity and diabetes management. They review risk factors and behaviors that can lead to obesity, as well as address systemic issues that can lead to disparities in diverse communities. They also highlight the multidisciplinary team approach...
Dr. Marcus D. Goncalves, the Ralph L. Nachman, M.D. Research Scholar and an assistant professor of medicine in the Division of Endocrinology, Diabetes and Metabolism at Weill Cornell Medicine, has been elected as a member of the American Society for Clinical Investigation (ASCI) for 2024....
A new study published in the Journal of Clinical Investigation has demonstrated that activating a pathway to promote cell division not only expanded the population of insulin-producing cells, but, surprisingly, also enhanced the cells’ function. The findings hold promise for future therapeutics that will improve the lives of individuals with type 2 diabetes—a condition that affects more than half a billion people worldwide.“That’s reassuring...
A cross-campus symposium brought together nearly 100 researchers from Weill Cornell Medicine and Cornell College of Human Ecology to catalyze the kind of interdisciplinary collaborations necessary to address the complex challenges of treating diabetes, obesity, and metabolic diseases.Titled "Metabolic Health: From Molecules to Populations," the symposium focused on three topics: diabetes at the molecular and cellular level, obesity and the biology of fat cells, and population-level...
This award is the largest federal grant ever given to Weill Cornell Medicine and represents 20 years of continuous funding for the CTSC under Dr. Imperato-McGinley’s direction.
The interdepartmental and interdisciplinary celebration of quality and patient safety initiatives included 27 projects from 13 departments across WCM, Lower Manhattan Hospital, NYP/Queens, and NYP/Brooklyn Methodist.
In a welcoming environment, the team is committed to providing individualized gender affirming hormone treatment. When feasible, the team suggests in person appointments for initial visits but will also accommodate patients for virtual visits.
Lectures were provided by WDOM faculty and keynote speaker, Dr. Drew Weissman, who played a major role in critical discoveries that allowed for the mRNA platform to be used in developing vaccines against SARS-CoV.
Sick Day Management for Adults with Type 1 Diabetes
